fda compounding semaglutide warning 2025 october Three Considerations When Prescribing Compounded GLP-1s — Little Health Law Blog — December 31, Semaglutide shortage ends as FDA

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

Vial size and treatment length are set in clinic

Each clinic has its own specific type of injection, and the components may differ from clinic to clinic

When storing multiple vials, placing them in secondary sealed bags with desiccants offers an additional safeguard

Why NAION Is Being Investigated in GLP-1 Lawsuits Medical researchers and attorneys are examining whether GLP-1 receptor agonist drugs including Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound may increase the risk of NAION in certain patients